Ascendis Pharma A (ASND) Notes Payables (2021 - 2026)

Ascendis Pharma A (ASND) has 6 years of Notes Payables data on file, last reported at $524.7 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 10.96% year-over-year to $524.7 million; the trailing twelve-month figure through Mar 2026 stood at $524.7 million (up 10.96% YoY), and the FY2025 full-year result was $499.8 million, up 0.79% from the prior year.
• Notes Payables advanced to $524.7 million in Q1 2026, from $499.8 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $598.2 million in Q3 2023 to a low of $395.4 million in Q4 2022.
• A 5-year average of $494.6 million and a median of $498.3 million in 2025 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables jumped 252.82% in 2022 and dropped 22.51% in 2024, its largest moves.
• Tracing ASND's Notes Payables over 5 years: stood at $395.4 million in 2022, then gained by 10.78% to $438.0 million in 2023, then advanced by 11.79% to $489.6 million in 2024, then rose by 2.08% to $499.8 million in 2025, then climbed by 4.98% to $524.7 million in 2026.
• Business Quant data shows ASND's Notes Payables at $524.7 million in Q1 2026, $499.8 million in Q4 2025, and $498.3 million in Q3 2025.